Minnesota FOIA #N009349302

Cost Reimbursable portion of sub- Pioglitazone-Metformin Combination Treatment for High Risk Oral Preneoplasia

This purchase order, issued on March 27, 2024, by the TWIN_CITIES agency, awards a contract to HENNEPIN HEALTHCARE RESEARCH INSTITUTE for the cost reimbursable portion of a treatment related to high risk oral preneoplasia, with an obligated amount of $47,400. The vendor, HENNEPIN HEALTHCARE RESEARCH INSTITUTE, located in Minneapolis, MN, USA, will provide the specified treatment. The award involves a single line item for the treatment, with a total purchase amount of $47,400. The procurement is a contract for research or medical treatment services, with no specific project duration indicated. The award is part of a research or medical services category, and the buyer is the Twin Cities. The vendor's address is 701 Park Avenue, HCMC Blue Building Lower Level, ZIP code 55415. The primary contact details for the buyer are not provided. Likely competitors for similar awards could include other research institutes or healthcare providers specializing in medical treatments or clinical research.

Description

Cost Reimbursable portion of sub- Pioglitazone-Metformin Combination Treatment for High Risk Oral Preneoplasia